Patients & Care Partners

Sage is pursuing new treatment pathways with the goal of improving brain health.

When everyone said brain health disorders were too tough to tackle, Sage said that they are too important not to. It’s why everything we do – from our journey of scientific discovery and development to our work with patients, care partners, and advocates – is laser-focused on our mission of making medicines that matter so people can get better, sooner.

Our depression, neurology and neuropsychiatry franchise programs aim to change how brain health disorders are thought about and treated.

The experiences of patients & care partners motivate us.

Advocacy

At Sage, identifying unmet patient needs drives our research and development focus. We seek to increase awareness and improve understanding of brain health disorders and integrate patient and care partner perspectives into every aspect of our work. Sage understands that brain health disorders affect not only individuals, but families, communities, and society. We engage with advocacy groups and those they serve to listen and learn from them as we rethink care and how to deliver it.

Clinical Trials

We are committed to developing new medicines to transform the lives of individuals with life-altering brain health disorders. As part of this mission, we conduct clinical trials to determine if our investigational medicines are safe and effective for individuals with a particular disease, disorder or condition which may allow us to seek the necessary regulatory approvals to provide wide access to these medicines.

Early Access

We understand that, in some cases, individuals with serious diseases or conditions may not be eligible for clinical trials and may not have other treatment options. Under very limited circumstances, we will consider making investigational medicines available for qualifying patients to treat a serious disease or condition outside of a clinical trial. “Early access”, “expanded access” and “compassionate use” are terms that describe this type of access.